Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

'Significant potential' for new swine flu strains
pigs
Regular outbreaks of influenza A viruses are seen in humans and pigs - most commonly H1 and H3 subtypes.
Largest ever dataset of antigenic variation created
 
Scientists say there is 'significant potential' for the emergence of new swine flu strains, due to the wide diversity of flu in pigs across multiple continents. These strains present a serious threat to public health, as they are no longer similar enough to current human flu strains for our immune systems to recognise them.

When flu viruses are transmitted from humans to pigs, they continue to evolve their surface proteins (or antigens), explained lead author Nicola Lewis from the University of Cambridge. This results in a large diversity of novel flu viruses, which can then be transmitted to pigs and humans.

Regular outbreaks of influenza A viruses are seen in humans and pigs - most commonly H1 and H3 subtypes. But there is a lack of data on the diversity of their antigens, which shapes their pandemic potential.

Dr Lewis and her team say they have created the largest and most geographically comprehensive dataset of antigenic variation. It encompasses nearly 600 flu viruses from 1930-2013, covering multiple continents including Europe, the US and Asia. Nearly 200 of the viruses had never been studied before.

Findings published in the journal eLife suggest the amount of variation in swine flu viruses is similar to that in H1 and H3 viruses seen in humans for the past 40 years. This has been driven by the frequent transmission of human viruses to pigs.

Dr Lewis commented: "Since most of the current swine flu viruses are the result of human seasonal flu virus introductions into pigs, we anticipate at least some cross-protective immunity in the human population, which could potentially interfere with a re-introduction of these viruses."

Lineages of human H1 and H3 viruses that were introduced earlier, however, pose the greatest risk to humans, Dr Lewis added. This is down to the low or negligible levels of cross-immunity predicted in people born since the 1970s.

Control strategies for swine flu vary by region. In the US, vaccination is used extensively to control flu in pigs, while some countries do not use vaccines at all and others produce herd-specific vaccines for individual producers. Co-author Colin Russell said the significant antigenic diversity seen in the data suggests it is "highly unlikely" that one vaccine strain per subtype would be effective globally, or even in a given region.

Researchers say their findings highlight the need for more focused surveillance in areas with high pig population density, such as China, as well as situations where pigs and humans are in close contact.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.